Aadi Bioscience to Present at Upcoming Investor Conferences
H.C. Wainwright 3rd AnnualPrecision Oncology Virtual Conference ,November 14, 2022 Neil Desai , Ph.D., Aadi Bioscience Founder and CEO, will participate in a fireside chat with the banking equity analyst, available on demand to registered conference attendeesJefferies London Healthcare Conference ,November 15-17, 2022 , inLondon Neil Desai , Ph.D., Aadi Bioscience Founder and CEO, andBrendan Delaney ,Aadi Bioscience COO, will take part in a hybrid presentation including a moderated Q&A session on Tuesday, November 15th, at3:35 am ET (8:35 am GMT )- Piper Sandler 34th Annual Healthcare Conference,
November 29-December 1, 2022 , inNew York Dr. Desai andMr. Delaney will participate in a fireside chat with the equity analyst on Wednesday, November 30, 2022 at12:30 pm ET
Replays of webcasts will be available on IR pages of the Aadi Biosciences website for approximately 30 days following each presentation.
Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval in November of 2021 and in February of 2022 commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Contact:
IR@aadibio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-at-upcoming-investor-conferences-301667554.html
SOURCE